Given the distinct genetic differences between pRCC and ccRCC, it is not surprising that therapies targeting the vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) have failed to benefit pRCC patients to the same extent as ccRCC patients 9. The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.